依达拉奉治疗急性脑梗死98例疗效观察

Observation on efficacy of Edaravone in the treatment of 98 patients with acute cerebral infarction

目的评价依达拉奉治疗急性脑梗死的疗效。方法选择急性脑梗死196例,随机分为2组:治疗组98例,给予依达拉奉和血塞通注射液,对照组98例,单用血塞通注射液,治疗后进行神经功能缺损评分比较。结果治疗后治疗组和对照组ESS评分均有改善(P<0.05),但治疗组改善更明显,且与对照组有显著性差异(P<0.05)。结论依达拉奉治疗急性脑梗死疗效确切,无明显不良反应,值得推广。

Objective To evaluate the efficacy and adverse reactions of Edaravone in the treatment of acute cerebral infarction（ACI）.Methods A randomized controlled study on 196 patients with ACI enrolled within 24 hours of onset was carried out.They were randomly allocated into treatment group（n= 98） and control group（n= 98）.Patients in both groups were given regular treatment.Patients in treatment group also received Edaravone injection 30 mg twice per day for 14 days.The neurological deficits and activities of daily living（ADL） of patients in both groups were assessed by Chinese stroke scale（CSS） and Barthel index respectively before and after the treatment.Clinical efficacy was evaluated according to changes of CSS and ADL scores on the 21st day.Results The efficacy rates in treatment group and control group were 89.8% and 60.2%,respectively（P0.05）.There was a significant difference in CSS scores and ADL scores between treatment group and control group（P0.05）.There was no distinct adverse reaction seen in these two groups.Conclusion Edaravone can improve impaired neurological function and activities of daily living in patients with acute cerebral infarction without obviously adverse reaction.Edaravone is effective and safe in the treatment of patients with acute cerebral infarction.It is worthy to be recommended for clinical application.